HealthDay News — Oral iron supplementation doesn’t improve the exercise capacity of iron-deficient patients with heart failure with reduced left ventricular ejection fraction (HFrEF), according to a study published in the May 16 issue of the Journal of the American Medical Association.

The research included 225 HFrEF patients who received either oral iron polysaccharide (150mg) or a placebo, twice daily for 16 weeks. The measured outcomes were changes in peak oxygen uptake and 6-minute walk distance.

The investigators found that after 4 months, patients who received iron supplementation did not have higher peak oxygen uptake than those receiving placebo. The team also found no significant differences between treatment groups in changes in 6-minute walk distance. 

Related Articles

“Among participants with HFrEF with iron deficiency, high-dose oral iron did not improve exercise capacity over 16 weeks,” the authors write. “These results do not support use of oral iron supplementation in patients with HFrEF.”


Continue Reading

Abstract/Full Text (subscription or payment may be required)